Jason Grebely

Professor Jason Grebely is a leading clinical epidemiologist at the University of New South Wales Sydney, where he serves as Head of the Hepatitis C and Drug Use Group within the Viral Hepatitis Clinical Research Program at the Kirby Institute. His work focuses on improving the health of people who use drugs, with particular emphasis on hepatitis C infection and harm reduction strategies.

Professor Grebely's research spans several key areas including hepatitis C epidemiology, testing methodologies, treatment strategies, and harm reduction approaches for people who use drugs. His work incorporates clinical trials, cohort studies, systematic reviews, and implementation science to evaluate novel strategies for enhancing hepatitis C testing (including point-of-care) and addressing harms related to drug use. He places strong emphasis on community engagement, ensuring his research is co-developed and co-designed with affected communities.

His recent publications (2023-2025) reveal a consistent focus on hepatitis C elimination strategies, with particular attention to marginalized populations including people who inject drugs and those in prison settings. Key themes include point-of-care testing implementation, treatment adherence challenges, reinfection risks, and innovative approaches to overcoming barriers in hepatitis C care. His work bridges clinical practice, public health policy, and community needs, with the goal of generating knowledge that can directly impact clinical guidelines and health service delivery.

• President of the International Network on Health and Hepatitis in Substance Users (INHSU)
• Leads research group managing two senior academic staff, four professional staff, and five PhD students
• Active in developing and implementing strategies to enhance hepatitis C testing and treatment access
• Works closely with affected communities to ensure research relevance

Professor Grebely's research program is characterized by its strong translational focus, aiming to generate new knowledge that can directly impact clinical practice, health service delivery, and public health policy. His work positions Australia at the global forefront of hepatitis C and drug use research, with direct implications for improving health outcomes among marginalized populations.